Supplemental
Supplemental Figure S1 . Circulating CD34+ cell AUC (h cells/µL) and peak circulating CD34+ cells/µl (*) in the 7 subjects who mobilized poorly following the 240 µg/kg dose of plerixafor (defined as those who had a peak circulating CD34+ counts ≤ 20 cells/µL with the conventional dose of plerixafor). Peripheral blood mononuclear cells were isolated using standard Ficoll-hypaque density gradient separation and inoculated at 1x10 5 cells/mL in three different methylcellulose culture media (MethoCult H4230; Stem Cell Technologies, Vancouver, Canada), supplemented with 5 µg/mL of recombinant human (rHu) erythropoietin (Epo; Amgen, Thousand Oaks, CA, USA), 10 ng/mL rHu granulocyte-macrophage colony stimulating factor (GM-CSF; Sandoz, East Hanover, NJ, USA), 10 ng/mL rHu interleukin-3, and 100 ng/mL rHu stem cell factor (SCF; R&D Systems, Minneapolis, MN, USA). Plated cells were incubated at 37 0 C with 5% CO 2 for 10-14 days.
Colonies were then counted, and pre-plerixafor dosing colonies were compared to post-plerixafor dosing colonies.
Supplemental Figure S3 . Estimated apheresis CD34+ cell yield
